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Summary
Background Chronic pulmonary infection with Pseudomonas aeruginosa is one of the most important causes of 
mortality and morbidity in cystic fibrosis. If antibiotics are commenced promptly, infection can be eradicated. The 
aim of the trial was to compare the effectiveness and safety of intravenous ceftazidime and tobramycin versus oral 
ciprofloxacin in the eradication of P aeruginosa.
Methods We did a multicentre, parallel group, open-label, randomised controlled trial in 72 cystic fibrosis centres 
(70 in the UK and two in Italy). Eligible participants were older than 28 days with an isolate of P aeruginosa (either the 
first ever isolate or a new isolate after at least 1 year free of infection). Participants were excluded if the P aeruginosa 
was resistant to, or they had a contraindication to, one or more of the trial antibiotics; if they were already receiving 
P aeruginosa suppressive therapy; if they had received any P aeruginosa eradication therapy within the previous 
9 months; or if they were pregnant or breastfeeding. We used web-based randomisation to assign patients to 14 days 
intravenous ceftazidime and tobramycin or 12 weeks oral ciprofloxacin. Both were combined with 12 weeks inhaled 
colistimethate sodium. Randomisation lists were generated by a statistician, who had no involvement in the trial, 
using a computer-generated list. Randomisation was stratified by centre and because of the nature of the interventions, 
blinding was not possible. Our primary outcome was eradication of P aeruginosa at 3 months and remaining free of 
infection to 15 months.  Primary analysis used intention to treat (powered for superiority). Safety analysis included 
patients who received at least one dose of study drug. TORPEDO-CF was registered on the ISRCTN register, 
ISRCTN02734162, and EudraCT, 2009-012575-10.
Findings Between Oct 5, 2010, and Jan 27, 2017, 286 patients were randomly assigned to treatment: 137 to intravenous 
antibiotics and 149 to oral antibiotics. 55 (44%) of 125 participants in the intravenous group and 68 (52%) of 
130 participants in the oral group achieved the primary outcome. Participants randomly assigned to the intravenous 
group were less likely to achieve the primary outcome, although the difference between groups was not statistically 
significant (relative risk 0·84, 95% CI 0·65–1·09; p=0·18). 11 serious adverse events occurred in ten (8%) of 
126 participants in the intravenous antibiotics group and 17 serious adverse events in 12 (8%) of 146 participants in 
the oral antibiotics group.
Interpretation Compared with oral therapy, intravenous antibiotics did not achieve sustained eradication of 
P aeruginosa in a greater proportion of patients with cystic fibrosis and was more expensive. Although there were 
fewer hospitalisations in the intravenous group than the oral group during follow-up, this confers no advantage over 
oral treatment because intravenous eradication frequently requires hospitalisation. These results do not support the 
use of intravenous antibiotics to eradicate P aeruginosa in cystic fibrosis.
Funding National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Cystic fibrosis is the most common, life-limiting, 
autosomal recessive disorder in populations with northern 
European ancestry and is less commonly reported in other 
ethnicities.1 There are around 30 000 affected individuals 
in the USA2 and 45 000 in Europe.3 Cystic fibrosis is a 
multisystem disorder caused by dysfunction of the cystic 
fibrosis transmembrane conductance regulator (CFTR) 
protein.1 In the lung, this dysfunction leads to failure of 
mucociliary clearance, retention of viscid secretions, 
recurrent infection, and bronchiectasis. Most people with 
cystic fibrosis die from respiratory failure.1 Life expectancy 
is between 40 years and 50 years.4 CFTR modulators, 
which treat the basic defect of cystic fibrosis, are now 
available for some patients, dependent on their age and 
specific mutations;5 however, for the foreseeable future, 
the early treatment of airways infection will remain a core 
component of cystic fibrosis treatment.
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Pseudomonas aeruginosa is a highly prevalent pathogen 
in cystic fibrosis that can be acquired from the 
environment or from other people with cystic fibrosis.6 
When airways infection first occurs, the organism is 
present in planktonic form and is susceptible to 
antibiotics. In the next state of infection, P aeruginosa 
forms biofilms in the airways, where the organisms are 
surrounded by exopolysaccharide matrix.7 This matrix 
confers resistance to antibiotics and host defences, and 
the infection becomes chronic.8 The presence of chronic 
P aeruginosa infection in cystic fibrosis is associated with 
increased mortality and morbidity (including a more 
rapid decline in lung function and more hospitalisations).9 
Most people with cystic fibrosis will have chronic airways 
infection with P aeruginosa by their mid-20s.10
Current evidence supports starting antibiotic regimens 
that aim to eradicate P aeruginosa as soon as the infection 
is diagnosed to disrupt nascent biofilms and prevent 
progression to chronic infection. However, evidence to 
suggest that any one regimen is better than another is 
absent.11 UK guidelines12 recommend an inhaled 
antibiotic (eg, colistimethate sodium) in combination 
with a systemic (ie, intravenous or oral) antibiotic 
because these are thought to be effective against different 
components of the P aeruginosa biofilm.8 US and 
European guidelines favour single agent inhaled 
tobramycin as first-line treatment.13,14 A regimen 
commencing with 2 weeks of intravenous antibiotics 
has been suggested to achieve a high eradication rate and 
is cost-effective;15 however, this claim is not supported 
by data from randomised controlled trials (RCTs). A 
course of intravenous antibiotics for P aeruginosa often 
involves the cost and inconvenience of a prolonged 
hospital admission and exposes patients to the risks 
of drug toxicity—particularly from aminoglycoside anti-
biotics. “What is the best way of eradicating Pseudomonas 
aeruginosa in people with cystic fibrosis?” was recently 
listed as one of the top 10 research priorities for cystic 
fibrosis in a partnership between people with cystic 
fibrosis and health-care providers.16
Research in context
Evidence before this study
Chronic pulmonary infection with Pseudomonas aeruginosa is an 
important cause of mortality and morbidity in cystic fibrosis. In 
US, UK, and European guidelines, inhaled antibiotics are first-line 
treatment and intravenous antibiotics second-line treatment for 
the eradication of early infection with P aeruginosa. Our Cochrane 
systematic review (last updated April 25, 2017) showed that 
nebulised antibiotics alone or in combination with oral 
ciprofloxacin are better than no eradication treatment for 
P aeruginosa. We repeated the literature search used in the 
Cochrane systematic review from Oct 11, 2016, to April 14, 2020, 
using the same search strategy: relevant trials were identified 
from the Cochrane Cystic Fibrosis and Genetic Disorders Group 
Trials Register using the terms “antibiotics” AND (“pseudomonas 
aeruginosa” OR “mixed infections”) AND (“eradication” OR 
“unknown”). We also searched the relevant clinical trials 
databases ClinicalTrials.gov, WHO ICTRP, and ISRCTN using the 
search terms “cystic fibrosis” AND “pseudomonas aeruginosa” 
AND “eradication”. Further details, including inclusion criteria 
and risk of bias assessment, can be found in our Cochrane 
systematic review. This search revealed a further six publications: 
two conference abstracts relating to the TORPEDO trial; 
an infection control study; two references to a study of oral 
azithromycin for eradication of P aeruginosa (as an adjunct to 
inhaled tobramycin); and a conference abstract relating to a 
further trial of azithromycin, which was under powered. 
We therefore conclude that, although intravenous antibiotics are 
widely used, there are no randomised controlled trials to 
investigate their effectiveness in eradicating P aeruginosa in cystic 
fibrosis. The TORPEDO-CF trial has been designed to find 
evidence of superiority of intravenous therapy, if such superiority 
exists. If intravenous antibiotics are not superior, then guidance 
can be given that will save health resources.
Added value of this study
Our randomised controlled trial is, to our knowledge, the first to 
compare the effectiveness of intravenous versus oral 
eradication therapy in children and adults with cystic fibrosis, 
and showed no significant difference in the number of 
participants achieving eradication. In the intravenous group, 
fewer patients were admitted to hospital in the 12 months 
following eradication. However, this confers no advantage as 
intravenous eradication usually requires admission whereas oral 
treatment does not. There was a considerable difference in cost 
between the two eradication regimens. The study has shown 
that oral eradication might be used with a cost saving of £5939 
(equivalent to 7543 US dollars) per patient. This is the first cost-
effectiveness study done as part of a randomised controlled 
trial of eradication.
Implications of all the available evidence
We found that intravenous antibiotics did not achieve eradication 
of P aeruginosa in a greater proportion of children and adults with 
cystic fibrosis than oral therapy. Intravenous therapy usually 
requires a prolonged admission to hospital, with consequent 
family disruption, as well as requiring significant health-care 
resource. Admission for intravenous therapy in the context of 
early P aeruginosa infection (and without the presence of a 
significant pulmonary exacerbation), in adults and children with 
cystic fibrosis, should not be recommended.
Our trial found that, even in the oral group (which had a better 
primary outcome), only around half of participants were free of 
infection 15 months after randomisation. Future research should 
aim to improve rates of eradication through approaches such as 
earlier detection of P aeruginosa and salvage therapy for failed 
eradication. It should also be a priority to evaluate the effects of 
CFTR modulators on acquisition and eradication of P aeruginosa.
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Based on the recommendations from a feasibility 
study,17 we designed an RCT to compare an intravenous 
with an oral regimen for eradication of P aeruginosa in 
children and adults with cystic fibrosis. Both treatment 
groups also received inhaled colistimethate sodium. We 
aimed to determine whether one regimen was superior 




TORPEDO-CF was a multicentre, parallel group, open-
label RCT, designed to test which of two antibiotic 
regimens was superior for eradication of P aeruginosa in 
children and adults with cystic fibrosis. The first patient 
was recruited on Oct 5, 2010, and the last follow-up 
visit occurred on April 10, 2018. The study was done in 
72 cystic fibrosis centres across two countries—70 in 
the UK and two in Italy.
The London Research Ethics Committee (London, UK) 
and Etico Regionale Della Liguria (Genoa, Italy) provided 
ethical approval. An independent data and safety 
monitoring committee and a trial steering committee 
provided trial oversight.
There were three major amendments to the protocol 
during the trial: the follow-up period was defined as 
15 months from start of allocated treatment (rather than 
from randomisation) to avoid bias due to delays in 
starting intravenous treatment (version 3.0; Sept 1, 2010); 
increased flexibility in dosing regimens, in line with 
national clinical guidelines (version 4.0; Dec 13, 2011); 
and intravenous treatment could be given at home 
(version 5.0; Jan 11, 2012). Full details of all amendments 
are given the final trial protocol, version 9.0 (Oct 12, 2016; 
appendix pp 63–79; HTA monograph). The protocol is 
also available on the sponsor’s website.
Participants
Eligible participants had a confirmed diagnosis of cystic 
fibrosis; a recent isolation of P aeruginosa from cough 
swab, sputum (spontaneous or induced), or broncho-
alveolar lavage; were aged older than 28 days; and were 
either Pseudomonas naive (ie, never previously isolated 
P aeruginosa) or were Pseudomonas free (ie, infection-free 
for ≥1 year). Participants were required to start allocated 
treatment within 21 days from the date of the positive 
microbiology report. Participants were excluded if 
the P aeruginosa was resistant to one or more of the 
trial antibiotics; if they had a contraindication to any 
of the trial antibiotics; if they were already receiving 
P aeruginosa suppressive therapy (eg, an inhaled anti-
biotic); if they had received any P aeruginosa eradication 
therapy within the previous 9 months; or if they were 
pregnant or breastfeeding. Patients could participate in 
the TORPEDO-CF trial once only and could not be 
randomly assigned within 4 weeks of taking part in 
another intervention trial.
Eligible participants were identified by the principal 
investigator in each participating centre. Written informed 
proxy consent was obtained from parents or guardians of 
children aged younger than 16 years (with assent from the 
young person) or from the patient themselves if the 
participant was aged 16 years or older.
Randomisation and masking
Participants were randomly assigned to either intravenous 
or oral antibiotic therapy by the principal investigator or 
a delegated clinician at the site using a secure web-
based randomisation system. The randomisation system 
was controlled centrally by the Liverpool Clinical Trials 
Centre (University of Liverpool, Liverpool, UK) to ensure 
allocation concealment, which was maintained by using a 
secure web based randomisation system. Randomisation 
lists were generated by a statistician who had no involve-
ment in the trial using a computer-generated list, in a 
1:1 ratio, using block randomisation with random variable 
block length (initial block length of three and then random 
block sizes of two and four). Randomisation was stratified 
by centre, but the details were not disclosed to investigators. 
After entry of participant details, treatment allocation was 
displayed on a secure webpage and an email confirmation 
sent to the principal investigator.
Procedures
Eligible and consenting participants were randomly 
assigned to receive either 14 days of intravenous 
ceftazidime at 50 mg/kg three times daily (maximum 
3 g per dose) and intravenous tobramycin at 10 mg/kg 
once daily (maximum 660 mg/day), or 12 weeks treatment 
with oral ciprofloxacin at 20 mg/kg (maximum 750 mg) 
twice daily. For children aged younger than 5 years, 
ciprofloxacin at 15 mg/kg twice daily could be used. 
Patients in both treatment groups were treated 
concurrently with 12 weeks of nebulised colistimethate 
sodium (1 megaunit twice daily for children aged 2 years 
or younger and 2 megaunits twice daily for children aged 
older than 2 years and adults). Duration of intravenous, 
oral, and inhaled therapies was consistent with UK Cystic 
Fibrosis Trust Guidelines.12 Participants who had a 
subsequent growth of P aeruginosa during the trial period 
were treated as per local guidelines.
A participant’s adherence to allocated therapy was 
monitored using participant-completed treatment diaries. 
Participants randomly assigned to intravenous antibiotic 
therapy could have the intravenous component of their 
regimen in hospital or at home.
Participants were followed up from the time of 
randomisation to at least 15 months, with trial visits at 
months 3, 6, 9, 12, 15, 18, 21, and 24. The 3-month visit 
window was between days 2 and 14 after treatment 
discontinuation, and the 15 month visit window was 
between 7 days before the scheduled visit date and 14 days 
afterwards. Other visits were allowed 7 days either side of 
the scheduled dates. In participants who were old enough 
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and able to do the procedure, we measured spirometry 
and collected sputum. Cough swabs were taken from 
younger children. The initial specimen of P aeruginosa 
and any organisms identified during a recurrent infection 
were sent to Public Health England’s AMRHAI Reference 
Unit (Colindale, UK) for strain typing by variable number 
tandem repeat (VNTR) analysis at nine loci.18
Outcomes
The primary outcome was eradication of P aeruginosa 
from respiratory samples (cough swab, sputum, or 
bronchoalveolar lavage) at 3 months from commencing 
trial treatment and remaining free of infection to 
15 months. We chose 12 months, following completion of 
eradication, as a reasonable period to evaluate whether 
eradication was sustained. Some participants did not have 
samples collected during the pre-specified protocol 
windows for the primary outcome at 3 months and 
15 months. It was therefore decided, during a blind data 
review after trial completion, to extend the window at 
which the 3 month sample could be taken to 4 weeks either 
side of the expected visit date, providing treatment had 
ceased at least 48 h before sampling. Similarly, the window 
was extended to four weeks either side of the expected 
15 month visit date. This decision was made to avoid 
excluding patients whose samples were taken outside the 
protocol-specified window. Secondary outcomes that 
utilised these sample results included time to recurrence 
of the original P aeruginosa infection and re-infection with 
a different genotype of P aeruginosa or other respiratory 
organisms. To avoid excessive participant burden, speci-
mens for microbiology were collected at routine clinic 
visits. Data on secondary outcomes, including forced 
expiratory volume in 1 s (FEV1), forced vital capacity (FVC), 
forced expiratory flow in mid expiration (FEF25–75), oxygen 
saturation, height, weight, body-mass index (BMI), 
number of pulmonary exacerbations,19 number of hospital 
admissions, number of days spent as an inpatient, carer 
and participant burden, were collected at baseline and at 
all of the routine trial visits.
Quality of life (QOL) and health-related QOL 
instruments, CFQ-R20 and EQ-5D-3L21 respectively, were 
completed by the participant, carer, or both (dependent 
on age) and collected at baseline and then at months 3, 
15, and 24. The EQ-5D-3L is a generic measure frequently 
used to measure health status and can be used to 
calculate quality-adjusted life-years (QALYs).22 Despite 
the EQ-5D-3L being designed primarily for adults, it is 
still advocated for use in children for reasons of 
comparability.23 Bespoke health service use diaries were 
collected (UK sites only) at baseline (completed 
retrospectively) and months 3, 6, 9, 12, and 15 (completed 
prospectively) to calculate cost per patient (from the 
National Health Service and Personal Social Services 
perspective) and assess incremental cost-effectiveness.
An assessment of adverse events was undertaken at 
each trial visit until 28 days after treatment cessation. All 
serious adverse events were recorded but only those 
serious events where the causal relationship to the trial 
treatment had been assessed and judged by the principal 
investigator to be possibly, probably, or almost certainly 
related to the trial treatment and had occurred within the 
reporting timeframe were expedited.
Statistical analysis
To inform the sample size calculation, data on the 
number of patients with successful eradication of 
P aeruginosa 3 months from the start of treatment and 
remaining free of infection to 15 months were obtained 
from an audit of all current cystic fibrosis patients at 
Alder Hey Children’s Hospital (Liverpool, UK). Data were 
included for treatments given from 1994–2007 treated 
according to standard UK CF Trust Guidelines.12 Data on 
48 children were available. Infection was eradicated at 
3 months in 37 (77%) and 28 (58%) of 48 children 
remained infection-free to 15 months. For 90% power at a 
5% level of significance (two-sided), to detect a difference 
between groups of 20% (between 55% and 75% successful 
eradication), 128 participants were required in each 
group. A 20% difference between the two treatment 
regimens was deemed to be of clinical importance, since 
the more intensive intravenous treatment would need to 
be justified by a substantial benefit. We estimated that 
10% of participants in each treatment group would not 
provide primary outcome data giving a recruitment target 
of 286 participants.
No formal interim analysis was planned, but analyses of 
the accumulating data on recruitment, protocol deviations, 
baseline characteristics, adherence, withdrawals, missing 
data, and safety data were performed annually for review 
by the independent data and safety monitoring committee. 
No member of the trial team, apart from the nominated 
statisticians, had access to these data.
All analyses were pre-specified in a statistical analysis 
plan.24 Evaluation of clinical effectiveness followed the 
principle of intention to treat (ITT) as far as was practically 
possible. We analysed safety in patients who received at 
least one dose of their allocated trial medication (the 
safety population). Analyses were performed using SAS, 
version 9.3, or later (North Carolina, USA).
For the primary outcome we calculated the relative risk 
(RR) and 95% CI, along with a two-sided p value from a 
χ² test. Several sensitivity analyses were prespecified to 
test the robustness of this analysis. For time to recurrence 
of the original P aeruginosa infection, we analysed data 
using the log-rank test, presenting the data as a Kaplan-
Meier plot, with a Cox proportional hazards model 
adjusted for baseline variables used as appropriate to 
calculate the hazard ratio and 95% CI. We used a repeated 
measures random effects model to analyse spirometric 
data (Quanjer GLI-2012 regression equations),25 oxygen 
saturation, Z scores for anthropometric data (children), 
BMI (adults), and QOL data. The dependent variables 
were the post baseline values and covariates were 
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baseline values, treatment, time of follow-up measure-
ment, and treatment by time of follow-up measurement 
interaction. The mean differences between the two treat-
ment groups at 15 months were calculated, presented 
with 95% CIs and p values. Pulmonary exacerbations 
were as defined by Rosenfeld and colleagues.19 We 
compared the number of exacerbations per participant in 
the 15 months from randomisation, between study 
groups, using the Mann-Whitney test. We compared the 
number of inpatient days in each group during the 
treatment phase and the number of inpatient days during 
the 12 months after eradication treatment was complete 
using the Mann-Whitney test. In the intravenous 
group, we excluded the number of days of intravenous 
anti biotics given in hospital (as mandated by the 
protocol). We compared the proportion of patients who 
were admitted to hospital at least once with a χ² test 
between groups.
Economic analysis
A prospective economic evaluation was done alongside 
the RCT to assess the cost-effectiveness of oral versus 
intravenous antibiotic therapy. The primary analysis 
used a National Health Service and Personal Social 
Services perspective for the collection and incorporation 
of resource use. In the oral versus the intravenous 
therapy groups, we compared the incremental cost per 
successful P aeruginosa infection eradication from 
3 months through to 15 months post randomisation. The 
time horizon for the analysis was 15 months post 
randomisation.
In the secondary analysis, utility values and survey 
timepoints were used to generate QALYs using the area 
under the curve method. Utilities were calculated from 
the EQ-5D-3L questionnaire, completed by patients or by 
proxy (carers), by using societal preference weights.21 
QALYs were calculated based on both 15-month and 
24-month horizons. Secondary analysis measured the 
incremental net monetary benefit (INMB) of treating 
patients with oral versus intravenous antibiotics within a 
cost-utility analysis. The INMB was calculated by 
subtracting the change in costs (oral vs intravenous) from 
the change in QALYs, valued at the £20 000 per QALY 
threshold, as typically used by the National Institute for 
Health and Care Excellence (NICE).26 A positive INMB 
implies that oral treatment is more cost-effective than 
intravenous treatment.27 Sensitivity analyses explored key 
structural uncertainties in the analysis identified a priori 
including the use of the specialised cystic fibrosis 
reimbursement tariff for patients, rather than activity-
based costing, as well as also including societal costs.
Total resource use and costs for each patient within the 
clinical trial were calculated. All costs were calculated in 
GBP using the price year 2016/17 (appendix pp 1–5). 
Where possible, unit costs were sourced from national 
databases (appendix pp 1–5). Missing resource utilisation 
data and utility values were multiply imputed 
Figure 1: Trial profile
*Multiple screenings were allowed; therefore, the number of reasons is greater than the number of patients 
excluded. †Patient randomly assigned but all data completely removed because sign off from the principal 
investigator could not be obtained. ‡12 excluded from primary analysis set because no sample at 15-month 
window. §11 excluded from safety analysis set because they did not receive any allocated treatment. ¶18 excluded 
from primary analysis set because no sample at 15-month window. ||Patient was randomly assigned, but all data 
were removed because principal investigator sign off could not be obtained. **Two excluded from safety analysis 
set because they did not receive any allocated treatment.
1308 assessed for eligibility*
286 randomised
1022 were excluded* 
 554 ineligible  
  4 younger than 28 days old 
  5 known to be pregnant 
  168 not P aeruginosa free  
  20 not able to commence treatment
  49 had antibiotic resistance  
  211 receiving P aeruginosa treatment 
  29 hypersensitivity  
  7 contraindications to trial drug 
  47 receiving an inhaled anti-pseudomonal
  antibiotic
  22 previous randomisation
  14 participation in another trial
  22 poor compliance 
  18 did not identify P aeruginosa
  1 unknown
 193 not approached
 113 clinical decision
 11 family circumstances
 2 no bed
 25 patient missed
 4 patient transferred
 12 social concerns
 8 language barriers
 4 other
 14 no reason given
 486 approached but did not consent 
324 did not want intravenous intervention
  34 did not want oral intervention
  7 did not want follow-up
  3 said no to research
  7 said no to randomisation
  4 did not want eradication therapy
  22 family circumstances
  1 leaving country
  4 unclear
  80 no reason given
 3 reason missing
137 allocated to intravenous antibiotic therapy 
 126 received allocated intervention
 11 did not receive allocated intervention
125 in primary analysis set‡
126 in safety analysis set§
 5 withdrawn from trial 
29 discontinued intravenous antibiotic
 therapy
149 allocated to oral antibiotic therapy
 146 received allocated intervention
 2 did not receive allocated intervention
 1 unknown†
130 in primary analysis set¶||
146 in safety analysis set**
16 withdrawn from trial 
24 discontinued oral antibiotic therapy
Articles
980 www.thelancet.com/respiratory   Vol 8   October 2020
(appendix pp 22, 26). Costs or outcomes beyond 
12 months were not discounted because of the short time 
horizon of the trial. Regression analysis for incremental 
costs and outcomes were adjusted for baseline utility and 
age because of the marked range of ages in this study. To 
account for statistical uncertainty and the correlation 
between costs and patient outcomes, the data were 
bootstrap sampled with replacement 2000 times.
TORPEDO-CF was registered with ISRCTN, 
ISRCTN02734162, and EudraCT, 2009-012575-10.
Role of the funding source
The trial was conceived after a feasibility study17 
commissioned by the funder, the UK National Institute 
for Health Research (NIHR) Health Technology Assess-
ment Programme. For TORPEDO-CF, the funder of 
the study had no role in data collection, data analysis, 
data interpretation, or writing of the Article. The 
corresponding author had full access to all the study 
data and had final responsibility for the decision to 
submit for publication.
Results
The first participant was randomly assigned on Oct 5, 2010, 
and the final participant on Jan 27, 2017. 1308 patients from 
72 centres were screened for eligibility; 1022 did not meet 
the eligibility criteria (figure 1). 286 patients from 61 centres 
(range 1–22 patients per site) were randomly assigned to 
treatment: 137 to intravenous antibiotic therapy and 149 to 
oral antibiotic therapy. 285 participants were included in 
the ITT analysis. One patient was excluded after 
randomisation because principal investi gator approval was 
not provided at database lock and therefore the participant’s 
data could not be used. Of 137 participants in the 
intravenous group, 11 (8%) did not receive treatment 
(neither allocated intervention nor colistimethate sodium) 
and 29 (21%) stopped treatment early. In the oral group, 
two (1%) of 148 participants did not start treatment and 
24 (16%) stopped treatment early. The most common 
single reason for not completing allocated treatment in the 
intravenous group was difficulty with intravenous access 
(12 [30%] of 40), and an adverse event was the most 
common reason in the oral group (13 [50%] of 26).
Baseline participant characteristics in each group are 







Infants and toddlers 
(28 days to 23 months)
42 (31%) 28 (19%)
Children (2 to 11 years) 71 (52%) 92 (62%)
Adolescents (12 to 17 years) 18 (13%) 19 (13%)
Adults (18 to 64 years) 6 (4%) 9 (6%)
Sex
Male 63 (46%) 67 (45%)
Female 74 (54%) 81 (55%)
Pseudomonas aeruginosa
Naive 81 (59%) 93 (63%)
Free 56 (41%) 55 (37%)
Pseudomonas aeruginosa confirmed by
Bronchoscopy lavage 0 3 (2%)
Cough plate 5 (4%) 4 (3%)
Cough swab 91 (66%) 91 (61%)
Cough swab and sputum 
sample
0 1 (1%)
Cough swab and throat 
swab
0 1 (1%)
Oropharyngeal aspirate 1 (1%) 0
Nasopharyngeal aspirate 0 1 (1%)
Sputum sample (not 
induced)
34 (25%) 39 (26%)
Sputum sample (induced) 3 (2%) 5 (3%)
Throat swab 2 (1%) 3 (2%)
Unknown 1 (1%) 0
Other micro-organisms detected
Candida albicans 11 (8%) 17 (11%)
MRSA† 0 2 (1%)
Burkholderia cepacia complex 0 0
Aspergillus fumigatus 2 (1%) 2 (1%)
Other organisms 26 (19%) 31 (21%)










70 (51%) 90 (61%)
p·Phe508del and other 40 (29%) 43 (29%)
p·Phe508del and unknown 4 (3%) 5 (3%)
Other and other 12 (9%) 7 (5%)
Unknown 11 (8%) 3 (2%)
Pulmonary exacerbation20 
present
18 (13%) 17 (11%)
BMI Z score (paediatric)† n=125; 0·3 (1) n=131; 0·3 (0·9)
BMI (adults; m/kg²)† n=6; 24·6 (1·8) n=9; 23·2 (2·3)
Time from P aeruginosa 
isolation to treatment 
initiation (days)†
n=126; 9 (5) n=145; 7 (5)
FEV1 percentage predicted (l)† n=67; 86·6 (15·8) n=70; 85·7 (16)
FVC percentage predicted (l)† n=67; 92·2 (15·5) n=70; 95·1 (14·5)
FEF25–75 %predicted (l)† n=44; 72·7 (26·6) n=53; 70·6 (30·3)
O2 saturation (%)† n=118; 97·7 (1·4%) n=133; 97·7 (1·7%)
Data are n (%), mean (SD) or n/N (%). MRSA=methicillin resistant Staphylococcus 
aureus. BMI=body-mass index. *Date of birth was not provided for two participants 
to allow age to be calculated. Age at randomisation was provided after database 
lock and analysis and added to the baseline table manually. †Data not available for 
all randomly assigned patients.
Table 1: Baseline characteristics of the intention-to-treat population
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of children aged 28 days to 23 months were randomly 
assigned to the intravenous group (42 [31%] of 137) than 
the oral group (28 [19%] of 146), but there were no other 
notable imbalances in baseline characteristics. None of 
the baseline samples that confirmed initial infection with 
P aeruginosa were resistant to any of the study drugs. 
Randomisation was stratified to ensure approximately 
equal numbers of participants in each group within a 
centre. Due to some sites recruiting small numbers and 
an initial block size of three participants, fewer 
participants were allocated to the intravenous group. 
Only 15 (5%) participants were adults (ie, aged ≥18 years).
Participants in the intravenous group received a mean 
of 11·5 days (SD 5·3) of ceftazidime and 11·0 days (5·1) 
of tobramycin (protocol-specified duration 10–14 days) 
based on data collected from 137 participants. Of the 
126 participants who received at least one dose of 
intravenous treatment, 67 (53%) received all doses in 
hospital and 58 (46%) received some treatment at home 
(data were missing for one participant). In the oral group, 
the protocol specified 168 doses of ciprofloxacin over 
84 days and the mean adherence rate was 93·2% 
(SD 17·3) based on data from 105 participants who 
returned fully completed treatment diaries. The protocol 
specified 84 days of colistimethate sodium for both 
groups. The mean adherence rate (over the first 84 days) 
was 82·1% (31·5) in the intravenous (n=97) and 91·6% 
(19·0) in the oral group (n=105).
We excluded 30 participants from the primary analysis 
(12 intravenous and 18 oral) in whom P aeruginosa was 
not detected after completion of eradication, but who did 
not have a sample taken at the 15 month time window. 
The primary outcome (successful eradication at 3 months 
and remaining infection free through to 15 months) was 
achieved by 55 (44%) of 125 participants in the 
intravenous and 68 (52%) of 130 participants in the oral 
group. Participants who were randomly assigned to the 
intravenous group had a reduced chance of having 
successful eradication of P aeruginosa 3 months after the 
start of treatment and remaining infection free through 
15 months, although this was not statistically significant 
(risk difference –0·08, 95% CI –0·21 to 0·04; relative risk 
[RR] 0·84, 95% CI 0·65 to 1·09; p=0·18). The types of 
samples that confirmed participants had a recurrence of 
P aeruginosa (post hoc) and the number of these samples 
that were resistant to any of the study drugs (post hoc) 
are provided in the appendix (p 6).
Five sensitivity analyses confirmed the conclusion of 
the primary analysis (p 7). An additional sensitivity 
analysis, where a logistic regression was fitted including 
centre as a random effect, confirmed centre had no effect 
on the primary results (p=0·22). A post-hoc analysis of 
time to P aeruginosa isolation found that P aeruginosa 
recurrence occurred sooner in the intravenous than the 
oral group, but this was not statistically significant 
(hazard ratio 1·31; 95% CI 0·93 to 1·85; p=0·12; figure 2). 
Two post-hoc analyses were done comparing the 
proportion of participants in whom infection was 
successfully eradicated by 3 months and subgroup 
analyses of patients who were P aeruginosa naive and 
P aeruginosa free. The first post-hoc analysis showed no 
significant difference between treatment groups 
(RR 0·92, 95% CI 0·85 to 1·00; p=0·04). In participants 
who were P aeruginosa free, the primary outcome was 
achieved by 23 (47%) of 49 patients in the intravenous 
and 21 (42%) of 50 patients in the oral group. Participants 
who were P aeruginosa free and randomly assigned to the 
intravenous group had an increased chance of having 
successful eradication of P aeruginosa 3 months after the 
start of treatment and remaining infection-free through 
15 months compared with the oral treatment group, 
although this was not statistically significant (risk 
difference 0·05, 95% CI –0·15 to 0·24; RR 1·12, 95% CI 
0·72 to 1·74). In participants who were P aeruginosa 
naive, the primary outcome was achieved by 32 (42%) of 
76 patients in the intravenous group and 47 (59%) of 
80 patients in the oral group. Participants who were 
P aeruginosa naive and randomly assigned to the 
intravenous group had a reduced chance of having 
successful eradication of P aeruginosa 3 months after the 
start of treatment and remaining infection free through 
15 months compared with the oral treatment group (risk 
difference –0·17, 95% CI –0·32 to –0·01; RR 0·72, 
95% CI 0·53 to 0·99). A Mantel-Haenszel test for 
interaction was done and the relative risks were not 
significantly different between the two subgroups 
(p=0·19).
Samples were available for VNTR typing at baseline 
and P aeruginosa infection recurrence was noted for 
42 participants (25 in the intravenous and 17 in the oral 
group). Using this method, 19 (76%) of 25 participants in 
the intravenous group and 12 (71%) of 17 participants in 
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the oral group had the same strain of P aeruginosa at 
baseline and recurrence. Because of the small number of 
participants included, caution is required in interpreting 
the analysis of the time to recurrence of the original 
P aeruginosa infection (appendix p 8) and the analyses 
of re-infection with a different and distinct genotype of 
P aeruginosa (appendix p 9). We assessed the effect 
of the treatment regimen on various measures of 
lung func tion (in participants aged 5 years and older) 
and found no evidence of an effect over time on 
percentage predicted FEV1 (estimated mean difference 
for intravenous compared with oral treatment 2·08, 
95% CI –0·99 to 5·14; p=0·18), percentage predicted 
FEF25–75 (3·46, –3·74 to 10·66; p=0·35), or oxygen 
saturation (0·05, –0·20 to 0·29; p=0·71). FVC was 
significantly better in the intravenous group than the oral 
group (3·14, 0·15 to 6·14; p=0·04); however, this finding 
should be interpreted with caution because there was no 
adjustment for multiple testing (table 2). Similarly, BMI 
(adults) was significantly lower in the intravenous group 
than the oral group (–0·73, –1·39 to –0·08; p=0·029), but 
this finding was based on a small number of adults with 
available data (n=13). There was no evidence of an effect 
at 15 months on oxygen saturation or on height for age 
Z score, weight for age Z score, or BMI Z scores in 
children (table 2).
During the 15 month follow-up, 52 (36%) of 
146 participants in the oral antibiotic group and 38 (28%) 
of 137 in the intravenous group had a pulmonary exacer-
bation. The difference was not statistically signifi cant 
(RR 0·78, 95% CI 0·55–1·10; p=0·16). Significantly fewer 
participants in the intravenous group (40 [31%] of 129) 
than the oral group (61 [45%] of 136) were admitted to 
hospital in the 12 months after eradication treatment 
(RR 0·69, 95% CI 0·50 to 0·95; p=0·020). During the 
3 month treatment phase, the median hospital stay for 
participants in both groups was 0 days (range 0–29 for 
intravenous [n=135] and 0–15 for oral [n=143]; p=0·066). 
During the 12-month post-treatment period, the median 
hospital stay was also 0 days for both groups (range 0–69 
for intravenous [n=129] and 0–64 for oral [n=136]; 
p=0·005). There were no statistically significant differ-
ences between study groups for the number of partici-
pants who isolated Methicillin-resistant Staphylococcus 
aureus (MRSA), Burkholderia cepacia complex, Aspergillus 
spp, or Candida spp (table 3). The number of participants 
who grew other organisms of interest is reported in the 
appendix (p 10). No planned statistical analyses were done 
for these organisms.
The QOL questionnaire was only completed for or by 
participants aged 6 years and older (134 of 285 randomly 
assigned patients; intravenous group n=62, oral group 
n=72). 106 participants were included in the analysis of 
the majority of domains in the self-report questionnaire 
(some domains included 105 participants because of 
missing data). There were no statistically significantly 
differences between the two treatment groups at 
15 months across any of the domains in each question-
naire (appendix p 11). The median number of days of 
absenteeism from education or work for carers and for 
participants was not statistically significantly between 
the two treatment groups (appendix p 12).
126 non-serious adverse events were reported from 
60 (48%) participants in the intravenous group, and 
136 non-serious adverse events from 72 (49%) 
participants in the oral group. The three most common 
adverse events (>5% of participants in either group) 
were cough, upper respiratory tract infection, and 
productive cough (table 4). One adverse event (malignant 
melanoma), which was classified as severe, was deemed 
to be unrelated to the trial medication. Summary data 
for all non-serious adverse events are detailed in the 
appendix (p 13). 11 serious adverse events were reported 
from ten (8%) participants in the intravenous group and 
17 serious adverse events reported from 12 (8%) 
participants in the oral antibiotic group (table 5). No 
participants died or had any suspected unexpected 
serious adverse reactions.
In the economic evaluation, before adjusting for 
covariates, the oral group had larger follow-up costs 
(excluding intervention costs) than the intravenous 
group, predominantly reflecting greater costs associated 
with follow-up inpatient stays (appendix pp 16–18), with 
all other costs and resource use being similar between 








Percentage predicted FEV1 86·19 (1·10) 84·11 (1·10) 2·08 (–0·99 to 5·14) 0·18
Percentage predicted FVC 94·08 (1·08) 90·94 (1·08) 3·14 (0·15 to 6·14) 0·04
Percentage predicted FEF25–75 72·39 (2·73) 68·93 (2·45) 3·46 (–3·74 to 10·66) 0·35
Oxygen saturation 97·83 (0·09) 97·78 (0·09) 0·05 (–0·20 to 0·29) 0·7
Weight for age Z score 0·11 (0·05) 0·13 (0·05) –0·02 (–0·15 to 0·11) 0·79
Height for age Z score –0·34 (0·04) –0·31 (0·04) –0·03 (–0·13 to 0·07) 0·57
BMI Z score (paediatric) 0·34 (0·05) 0·33 (0·05) 0·01 (–0·14 to 0·16) 0·91
BMI (kg/m²; adult) 23·51 (0·22) 24·25 (0·24) –0·73 (–1·39 to –0·08) 0·029
Data are mean (SE) estimated from model, unless otherwise indicated. Random effect model contains: baseline value, 
treatment group, time of follow-up measurement, and treatment group by time of follow-up measurement 
interaction term as independent variables in the model. BMI=body mass index.






Relative risk (95% CI) p value
Methicillin-resistant 
Staphylococcus aureus
4/135 (3%) 2/140 (1%) 2·07 (0·39–11·14) 0·44
Burkholderia cepacia Complex 2/135 (1%) 4/139 (3%) 0·51 (0·10–2·76) 0·68
Candida spp 55/136 (40%) 55/142 (39%) 1·04 (0·78–1·40) 0·77
Aspergillus spp 14/135 (10%) 20/139 (14%) 0·72 (0·38–1·37) 0·31
Data are n/N (%), unless otherwise indicated.
Table 3: Other sputum or cough microbiology over 15 months after randomisation
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QOL, without adjusting for covariates, was similar across 
the two groups for each timepoint (appendix p 22).
Incremental total costs, outcomes, and cost-effectiveness 
for the primary and secondary analyses, adjusted by 
baseline characteristics, are shown in table 6. Overall, oral 
treatment was less costly than intravenous treatment 
when including intervention costs, with the incremental 
difference in mean costs being –£5939 (95% CI –7107 to –4666) 
after adjusting for baseline covariates. Much of the overall 
total cost difference reflects the inpatient stay cost for 
intra venous therapy. In sensitivity analyses, where 
specialised cystic fibrosis tariffs were used to cost therapy 
and hospitalisations, the incremental difference in costs 
was lower, at –£653 (–1198 to –80) for oral treatment 
versus intravenous treatment (appendix p 23), reflecting 
the higher banding placed on reimbursement for follow-
up hospitalisations, which were greater in the oral group 
(appendix p 5). For a 15 month time horizon, patients on 
oral treatment gained 0·035 QALYs (95% CI –0·007 to 
0·088) versus patients receiving intravenous treatment. 
After 24 months, patients on oral treatment gained 
0·058 QALYs (–0·004 to 0·140) for oral versus intravenous 
treatment.
In all scenarios, including sensitivity analyses 
(appendix p 23), oral treatment led to reductions in costs 
versus intravenous treatment and was also more effective 
(oral dominates intravenous). For a cost-effectiveness 
threshold of £20 000 per QALY, oral treatment generated 
£6771 (95% CI 5027 to 7906) benefit per patient versus 
intravenous treatment. Cost-effectiveness planes and 
acceptability curves (appendix pp 24–25) show that the 
results were robust dependent on the threshold used for 
cost-effectiveness.
Discussion
We tested the hypothesis that an intravenous antibiotic 
regimen is more effective than oral treatment for 
eradicating P aeruginosa in people with cystic fibrosis. 
Inhaled colistimethate sodium was included in both 
regimens. Intravenous treatment was not superior in 
achieving the primary outcome, eradication of P aeruginosa 
at 3 months and remaining free of infection to 15 months. 
In the 12 months after completion of the eradication 
regimen, significantly fewer patients in the intravenous 
group were admitted to hospital than in the oral group. 
This difference might be because patients who have 
already had one hospital admission for eradication are less 
likely to accept a further admission in the subsequent 
12 months. Health-related QOL was similar in the 
two groups, suggesting 2 weeks of intravenous treatment 
did not have a negative effect.
A Cochrane systematic review11 has shown that 
eradication of P aeruginosa with an antibiotic eradication 
regimen in patients with cystic fibrosis is effective; 
however, no evidence exists favouring one eradication 
regimen over another. UK guidelines recommend inhaled 
colistimethate sodium and oral ciprofloxacin as first-line 
treatment.12 Guidelines from the USA13 and Europe14 
favour inhaled tobramycin as a single agent, but 
acknowledge that other regimens (including colisti-
methate sodium and ciprofloxacin) can be used. Our trial 
has shown that there is no advantage in choosing 
intravenous treatment as first-line treatment. When a 
regimen comprising inhaled colisti methate sodium and 
oral ciprofloxacin was compared with inhaled tobramycin, 
there was no difference in eradication rates,28 suggesting 
inhaled tobramycin would perform equally well against 
intravenous treatment. The eradication rates achieved in 
Intravenous antibiotic 
therapy (n=126)
Oral antibiotic therapy 
(n=146)
Total (n=272)
Events Participants Events Participants Events Participants
Any non-serious adverse 
event*
126 60 (48%) 136 72 (49%) 262 132 (49%)
Most common non-serious adverse events†
Cough 26 22 (17%) 28 23 (16%) 54 45 (17%)
Upper respiratory tract 
infection
15 11 (9%) 3 2 (1%) 18 13 (5%)
Productive cough 5 5 (4%) 8 8 (5%) 13 13 (5%)
Data are n or n (%). *Nine additional adverse events were reported by nine participants in the intravenous antibiotic 
therapy group and five adverse events from five participants in the oral antibiotic therapy group but have not been 
included here as they were the event of interest for the primary outcome (P aeruginosa isolation) so should not have 
been reported as an adverse event. Three additional adverse events were reported by three participants in the oral 
antibiotic therapy group but have not been included here as they contributed to the analysis of the outcome number 
of pulmonary exacerbations. †Reported by at least 5% of participants in either treatment group.






Events Participants Events Participants Events Participants
Gastrointestinal disorders 2 2 (2%) 1 1 (1%) 3 3 (1%)
General disorders and 
administration site conditions
1 1 (1%) 2 2 (1%) 3 3 (1%)
Hepatobiliary disorders 1 1 (1%) 0 0 1 1 (<1%)
Infections and infestations* 1 1 (1%) 7 6 (4%) 8 7 (3%)
Nervous system disorders 1 1 (1%) 0 0 1 1 (<1%)
Psychiatric disorders 0 0 1 1 (1%) 1 1 (<1%)
Renal and urinary disorders 1 1 (1%) 0 0 1 1 (<1%)
Respiratory, thoracic, and 
mediastinal disorders
0 0 6 5 (3%) 6 5 (2%)
Skin and subcutaneous tissue 
disorders
1 1 (1%) 0 0 1 1 (<1%)
Surgical and medical 
procedures
1 1 (1%) 0 0 1 1 (<1%)
Vascular disorders 2 2 (2%) 0 0 2 2 (1%)
Total* 11 10 (8%) 17 12 (8%) 28 22 (8%)
Data are n or n (%). *Three additional serious adverse events were reported by three participants in the oral antibiotic 
therapy group but have not been included here as they were the event of interest for the primary outcome 
(P aeruginosa isolation) so should not have been reported as a serious adverse event. One additional adverse event was 
reported by one participant in the oral antibiotic therapy group but has not been included here as it contributed to the 
analysis of the outcome number of pulmonary exacerbations.
Table 5: Serious adverse events, according to trial group
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our trial (44% intravenous and 52% oral) are less than 
those achieved in the ELITE trial29 of 28 days versus 
56 days of inhaled tobramycin (66–69% eradication at 
27 months). This might reflect the exclusion of 
pseudomonas antibody-positive patients from the ELITE 
trial.29 Our trial evaluating a single course of eradication 
treatment is not directly comparable with trials evaluating 
regular, cycled therapy such as the EPIC trial.30 Eradication 
treatment should be initiated as soon as possible after 
P aeruginosa is detected in respiratory secretions.31 A 
recent crossover trial32 of eradication in young children 
showed a much lower eradication rate in those who had 
placebo in the initial 28 day treatment period. In the 
TORPEDO-CF trial, the protocol mandated that the 
eradication regimen should start not more than 21 days 
after P aeruginosa isolation.
Our health economic evaluation showed a cost saving 
of £5939 (equivalent to US$7543) per patient with the use 
of oral versus intravenous treatment. The economic 
evaluation found that oral eradication therapy was likely 
to have similar effectiveness for the primary clinical 
measure, but that oral eradication was considerably 
cheaper. Consequently, there was high certainty that oral 
treatment was more cost-effective than intravenous 
therapy. In secondary analysis, using the EQ-5D-3L to 
calculate QALYs (commonly used for health technology 
assessment), oral therapy was also highly likely to be 
cost-effective versus intravenous therapy. However, 
estimates on QALYs and utility values reported in this 
study can only be considered indicative as EQ-5D-3L 
scores from proxy and self-reported instruments were 
combined.33
The TORPEDO-CF trial used a pragmatic design to 
minimise the burden of participation. Respiratory 
specimens for microbiology were collected at routine 
clinic visits, which meant that not all were obtained in 
the 3 week window at the end of the 15 month follow-up. 
To address this issue we extended the window to include 
patients with samples 4 weeks either side of 15 months 
and did a sensitivity analysis using the next sample 
collected after the 15 month window. We collected 
sputum or a cough swab when collection of sputum was 
not possible. We chose a minimum clinically important 
difference for the primary outcome of 20%. A difference 
of this size is plausible. In the largest trial30 of P aeruginosa 
eradication to date, a difference of 17% was seen in the 
rates of eradication between treatment groups. Discus-
sions with the patient community informed the design of 
the TORPEDO-CF trial and these discussions indicated 
that, if intravenous treatment was more effective, the 
magnitude of this effect should be sufficient to justify the 
inconvenience of hospital admission for intravenous 
antibiotics.
A strength of our study was the large sample size 
and the length of follow-up. In the first generation of 
placebo-controlled eradication trials, sample size was 
often small and microbiological eradication was reported 
immediately after the end of eradication treatment.34 
In 2012, a large RCT evaluating two 28 day eradication 
regimens showed that more than 60% of participants 
had further infection with P aeruginosa during a median 
follow-up of 16 months.35 Arguably, with longer follow-
up, recurrence of P aeruginosa will be influenced to a 
lesser degree by a single course of eradication treatment. 
Hence, the 12 months of post-eradication follow-up used 
in our study is reasonable.
Feasibility data suggested that 25% of eligible patients 
would be adults.17 However, we recruited only 15 adults 
out of a total sample size of 286 participants, because only 
a small number of adult centres participated. We therefore 
advise caution in applying these trial findings to the adult 
cystic fibrosis population. Many patients and families 
had a strong preference for one eradication regimen: 
324 declined to participate because they did not want 
intravenous therapy and 34 because they did not want an 
oral regimen. Our feasibility study suggested that 45% of 
parents and patients would consider participation. The 
consent rates achieved in TORPEDO-CF were lower, at 
286 (37%) of 772 eligible patients approached.
Patient engagement work identified P aeruginosa 
eradication (UK)16 and microorganism detection and 
treatment (USA)36 as important research priorities—both 
prioritised reducing treatment burden. Future studies 
should combine long-term follow-up with regimens to 
reduce recurrence after eradication. The 2018 OPTIMIZE 
trial37 used 18 months of oral azithro mycin as an adjunct 
to eradication with inhaled tobramycin, but found no 
difference in time to recurrence. When a treatment (such 
as intravenous antibiotics) is burdensome, but no more 
effective, it follows that patients should be offered an 
Incremental cost (£)* Incremental outcome* ICER Incremental net monetary 
benefit (£)†
Primary analysis: percentage successful eradication, NHS and 
PSS perspective costs, 15-month horizon, adjusted
–5938·5 (95% CI –7107·4 to –4666·3) 0·091 (95% CI –0·034 to 0·22) Oral dominates‡ NA§
Secondary analysis: 15-month horizon QALYs, NHS, and PSS 
perspective costs, covariate
–5938·5 (95% CI 7107·4 to –4666·3) 0·035 (95% CI –0·007 to 0·088) Oral dominates‡ 6770·8 (95% CI 5027·4 to 7906·2)
ICER=Incremental Cost Effectiveness Ratio. NHS=National Health Service. PSS=Personal Social Services. NA=not applicable. QALY=quality-adjusted life-years *Adjusting for baseline EQ5D and age (in days) in 
linear regression. †At a cost-effectiveness threshold of £20 000 per QALY. ‡Dominates (ie, more effective and less costly). §There is no societally accepted willingness-to-pay threshold associated with the primary 
outcome measure and so this is not reported.
Table 6: Incremental costs, outcomes, ICERs, and incremental net benefit between trial groups (oral vs intravenous)
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eradication regimen that is appropriate to their clinical 
condition and personal circumstances. P aeruginosa 
might be identified at the time of a pulmonary 
exacerbation when intravenous antibiotics are clinically 
indicated. In other cases, when the patient is asympto-
matic, oral eradication is appropriate. In our trial, only 
eight (13%) of 137 of patients in the intravenous group 
and 17 (11%) of 148 patients in the oral group had an 
exacerbation at baseline.
Intravenous treatment often entails hospital admission, 
requires intravenous access (which might be traumatic),38 
and carries the risk of side-effects, including nephro-
toxicity and ototoxicity with aminoglycosides such as 
tobramycin.39 Because there were no important clinical 
benefits to the use of intravenous over oral therapy, the 
large difference in cost suggests that oral therapy should 
usually be recommended for eradication of early infection 
with P aeruginosa in cystic fibrosis. If the findings of this 
trial are implemented in routine clinical practice, most 
patients will receive oral eradication treatment as an 
outpatient and many hospital admissions will be avoided, 
which in turn will reduce both treatment burden and 
health-care costs.
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